anyone else notice oral GLP-1 kicking in around week 56
Here it is: anyone else notice oral GLP-1 kicking in around week 56. One person, one log, no control group, so read it accordingly.
Why "oral" is doing two completely different jobs in the sentences people write here.
Oral semaglutide is a peptide co-formulated with an absorption enhancer, which is why it comes with food and water timing requirements. This compound is a non-peptide small molecule that activates the same receptor, formulated as an ordinary tablet.
The practical consequences differ enormously: no timing constraints, a conventional manufacturing route, different stability behaviour, and a different analytical problem for anybody trying to verify identity or purity. Whenever a thread here compares the two, check which sense of "oral" each half is using.
What is actually known, and what is being assumed.
Known: it is a small-molecule GLP-1 receptor agonist, dosed daily, with clinical programmes reporting in both obesity and type 2 diabetes. Its tolerability profile broadly resembles the class in the data published so far.
Assumed, frequently and confidently: that milligram comparisons with injectables mean something, that adherence is straightforwardly better because it is a tablet, that peptide purity discussions transfer to it. None of those hold. And nothing containing this compound is approved anywhere, which makes research-use-only material exactly that — not approved for human use.
Happy to answer the boring questions. Those are usually the ones worth asking.
best — the order this archive was captured in
Oral semaglutide is a peptide co-formulated with an absorption enhancer and carries food and water timing requirements. A small molecule does not have that constraint, which is the practical distinction.
Oral semaglutide is a peptide co-formulated with an absorption enhancer and carries food and water timing requirements.
This is the fact the whole board hangs on. Small molecule, not peptide.
The no-timing-restriction thing is the part I would care about most in practice, and it barely gets mentioned here.
daily dosing changes adherence in both directions
do not assume reconstitution intuitions apply, there is nothing to reconstitute
Holding off on any opinion until phase 3 reports. That is not a satisfying position and it is the honest one.
Agreed — non-peptide is the fact that everything else follows from, including the manufacturing and the analytics.
Not convinced. Oral semaglutide is a peptide formulated with an absorption enhancer; the comparison you are making does not hold.
a non-peptide agonist does not degrade the way a peptide does
the boards keep comparing it to injectables at matched doses, which is meaningless
Standing reminder: unapproved compound, research material is not for human use, and no schedules for other members.
Milligram-for-milligram comparison with an injectable peptide is not meaningful and I should not have made it.
oral and non-peptide is the whole engineering story
Yes. Oral peptide with an absorption enhancer and oral small molecule are completely different propositions.
Right, and comparing milligrams between a small molecule and a peptide is meaningless in either direction.
Yes — nothing containing this is approved anywhere, and the threads keep forgetting it.
Nothing containing this compound is approved by any regulator, and research-use-only material is not approved for human use.
Small fix — the two programme names got swapped upthread and it changes which population the figure came from.
Which programme and which readout are you quoting?
oral semaglutide is a peptide with an absorption enhancer, this is not that
- 1Standing reminder: unapproved compound, research material is not for human…10 comments in this branch · started by u/phase_two_pete
- 2do not assume reconstitution intuitions apply, there is nothing to…6 comments in this branch · started by u/piotr_bruun